PMID- 38048705
OWN - NLM
STAT- MEDLINE
DCOM- 20240304
LR  - 20240304
IS  - 1758-1052 (Electronic)
IS  - 0956-4624 (Linking)
VI  - 35
IP  - 4
DP  - 2024 Mar
TI  - Safety profiles of homologous and heterologous regimens containing three major 
      types of COVID-19 vaccine among people living with HIV.
PG  - 262-273
LID - 10.1177/09564624231220090 [doi]
AB  - BACKGROUND: Existing data on adverse effects (AEs) of homologous and heterologous 
      COVID-19 vaccine regimens among people living with HIV (PLHIV) are limited. 
      METHODS: A prospective cohort study was conducted among Thai PLHIV during 
      2021-2022. Vaccine types and AEs were collected using an online survey. RESULTS: 
      Of the 398 vaccinated PLHIV, 92% had CD4 count >/=200 cells/microL and 96% were 
      virologically suppressed at enrolment; 38% received two doses and 62% received 
      three doses of COVID-19 vaccines. Inactivated, viral vector and mRNA were the 
      most common vaccine types received as the first, second, and booster doses, 
      respectively. For the first and second vaccine doses, the most common AEs were 
      fever (15% and 11%) and injection site pain (11% and 11%). The mRNA vaccine 
      significantly caused more overall AEs, injection pain, fatigue, and rashes than 
      the other two types. For a booster dose, viral vector vaccine significantly 
      caused more injection site pain and headache than the other two types. The 
      majority of AEs of the first, second and booster doses spontaneously recovered 
      without treatment. By multivariable analysis, receipt of viral vector or mRNA 
      vaccine and age less than 40 years were independently associated with AEs of the 
      primary series vaccines, while having AEs from the previous dose and female sex 
      were independent factors associated with AEs of a booster vaccine. CONCLUSIONS: 
      Our study suggested the safety of homologous and heterologous regimens containing 
      the three types of COVID-19 vaccines among PLHIV and identified those who 
      required close monitoring for vaccine AEs.
FAU - Khawcharoenporn, Thana
AU  - Khawcharoenporn T
AUID- ORCID: 0000-0001-6093-2887
AD  - Division of Infectious Diseases, Department of Internal Medicine, Faculty of 
      Medicine, Thammasat University, Pathumthani, Thailand.
AD  - HIV/AIDS Care Unit of Thammasat University Hospital, Pathumthani, Thailand. 
      RINGGOLD: 37699
FAU - Hanvivattanakul, Sirashat
AU  - Hanvivattanakul S
AD  - Faculty of Medicine, Thammasat University, Pathumthani, Thailand. RINGGOLD: 37699
LA  - eng
PT  - Journal Article
DEP - 20231204
PL  - England
TA  - Int J STD AIDS
JT  - International journal of STD & AIDS
JID - 9007917
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (mRNA Vaccines)
SB  - IM
MH  - Female
MH  - Humans
MH  - Adult
MH  - COVID-19 Vaccines/adverse effects
MH  - Prospective Studies
MH  - mRNA Vaccines
MH  - *COVID-19/prevention & control
MH  - Pain
MH  - *HIV Infections
OTO - NOTNLM
OT  - COVID-19 vaccine
OT  - Safety
OT  - Thailand
OT  - adverse effects
OT  - human immunodeficiency virus
OT  - people living with HIV
COIS- Declaration of conflicting interestsThe author(s) declared no potential conflicts 
      of interest with respect to the research, authorship, and/or publication of this 
      article.
EDAT- 2023/12/05 00:41
MHDA- 2024/03/04 06:49
CRDT- 2023/12/04 18:06
PHST- 2024/03/04 06:49 [medline]
PHST- 2023/12/05 00:41 [pubmed]
PHST- 2023/12/04 18:06 [entrez]
AID - 10.1177/09564624231220090 [doi]
PST - ppublish
SO  - Int J STD AIDS. 2024 Mar;35(4):262-273. doi: 10.1177/09564624231220090. Epub 2023 
      Dec 4.